15 new drugs added to Medicare price negotiations
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices.
⚠️ 风险分析 中
摘要：美国医保药品价格谈判新增15种药物，可能影响药企定价策略与市场准入。
影响：相关制药企业面临政府主导的降价压力，可能影响其在美国市场的收入、利润及新药研发投资回报。
建议：药企需评估谈判对具体产品的影响，调整定价与市场策略，并关注后续法规动态以应对合规风险。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.